免疫治疗与头颈癌皮瓣重建术后伤口并发症的关系
这项多中心回顾性病例系列评估了接受消融和皮瓣重建手术并联合免疫治疗的头颈癌患者,发现术前免疫治疗单独与主要受区并发症风险升高相关(OR 3.7,p=0.04),但术前术后均治疗者未见此关联。结论提示术前免疫治疗可能与伤口并发症增加有关,需对照研究进一步明确。
要点
- 术前免疫治疗单独与主要受区并发症风险升高相关(OR 3.7,p=0.04)。
- 术前免疫治疗有供区并发症增多的趋势(OR 7.4,p=0.06)。
- 术前和术后均接受免疫治疗者未显示并发症风险显著增加。
核心结论
- 术前免疫治疗可能与头颈癌皮瓣重建术后伤口并发症增加有关。
研究设计与样本
- 回顾性多机构病例系列,评估接受消融和皮瓣重建手术并联合免疫治疗的头颈癌患者。
主要发现
- 基于患者或肿瘤特异性变量,并发症无统计学显著差异。
- 单独术前治疗显示主要并发症增加(OR 3.7,p=0.04),并有供区并发症增多的趋势(OR 7.4,p=0.06)。
临床怎么用
- 对于计划行皮瓣重建的头颈癌患者,术前免疫治疗需警惕主要受区并发症风险升高。
局限性
- 回顾性研究设计,样本量有限,需对照研究进一步明确关联及治疗潜在风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunotherapy agents are used to treat advanced head and neck lesions. We aim to elucidate relationship between immunotherapy and surgical wound complications. METHODS: Retrospective multi-institutional case series evaluating patients undergoing ablative and flap reconstructive surgery and immunotherapy treatment. MAIN OUTCOME: wound complications. RESULTS: Eight-two (62%) patients received preoperative therapy, 89 (67%) postoperative, and 33 (25%) in both settings. Forty-one (31%) patients had recipient site complications, 12 (9%) had donor site. Nineteen (14%) had major recipient site complications, 22 (17%) had minor. There was no statistically significant difference in complications based on patient or tumor-specific variables. Preoperative therapy alone demonstrated increased major complications (odds ratio [OR] 3.7, p = 0.04), and trend to more donor site complications (OR 7.4, p = 0.06), however treatment in both preoperative and postoperative therapy was not. CONCLUSIONS: Preoperative immunotherapy may be associated with increased wound complications. Controlled studies are necessary to delineate this association and potential risks of therapy.
引用
- Mays AC, Yarlagadda B, Achim V, et al. Examining the relationship of immunotherapy and wound complications following flap reconstruction in patients with head and neck cancer. Head Neck. 2021. PMID: 33417293. doi:10.1002/hed.26601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。